[Prevention and treatment of deep vein thrombosis with ximelagatran].
Caspary
L
L
Angiologische Gemeinschaftspraxis, Hannover. LCaspary@t-online.de
Bauersachs
R
R
Brehme
S
S
Creutzig
A
A
Harenberg
J
J
Hoffmann
U
U
Landgraf
H
H
Schellong
S
S
D000925:Anticoagulants / Q000627:therapeutic use; D001120:Arginine / Q000031:analogs & derivatives; D001384:Azetidines / Q000009:adverse effects / Q000627:therapeutic use*; D001596:Benzylamines; D000077425:Fondaparinux; D005998:Glycine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D024764:Hirudin Therapy; D006801:Humans; D010875:Pipecolic Acids / Q000627:therapeutic use; D011134:Polysaccharides / Q000627:therapeutic use; D011355:Prodrugs / Q000009:adverse effects / Q000627:therapeutic use*; D013449:Sulfonamides; D013917:Thrombin / Q000037:antagonists & inhibitors*; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000517:prevention & control*
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D010875:Pipecolic Acids; D011134:Polysaccharides; D011355:Prodrugs; D013449:Sulfonamides; C109573:melagatran; C426686:ximelagatran; D006493:Heparin; D001120:Arginine; D013917:Thrombin; C031942:argatroban; D000077425:Fondaparinux; D005998:Glycine